Jorge A Garcia
Overview
Explore the profile of Jorge A Garcia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
4557
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Domb C, Garcia J, Barata P, Mendiratta P, Rao S, Brown J
Ther Adv Urol
. 2024 May;
16:17562872241249073.
PMID: 38779496
Antibody-drug conjugates and bicycle toxin conjugates represent a tremendous advance in drug delivery technology and have shown great promise in the treatment of urothelial cancer. Previously approved systemic therapies, including...
3.
Purcell-Milton F, Kuznetsova V, Bai X, Coogan A, Martinez-Carmona M, Garcia J, et al.
Nanoscale Horiz
. 2024 Apr;
9(6):1013-1022.
PMID: 38597212
In recent years, extensive research efforts have been dedicated to the investigation of CdSe/CdS-based quantum-confined nanostructures, driven by their distinctive properties. The morphologies of these nanostructures have been shown to...
4.
Gupta S, Andreev-Drakhlin A, Fajardo O, Fasso M, Garcia J, Wee C, et al.
J Natl Cancer Inst
. 2023 Nov;
116(4):547-554.
PMID: 38036464
Background: This study examined real-world patients with locally advanced or metastatic urothelial carcinoma considered ineligible for platinum-containing chemotherapy in the first-line setting. Methods: This retrospective observational study used data from...
5.
Jang A, Lanka S, Ruan H, Kumar H, Jia A, Garcia J, et al.
Expert Rev Anticancer Ther
. 2023 Nov;
23(12):1251-1263.
PMID: 38030394
Introduction: Patients with metastatic prostate cancer, especially in the castrate-resistant setting, have a poor prognosis. Many agents have been approved for metastatic prostate cancer, such as androgen receptor pathway inhibitors,...
6.
Jang A, Lichterman J, Zhong J, Shoag J, Garcia J, Zhang T, et al.
Hum Vaccin Immunother
. 2023 Nov;
19(3):2276629.
PMID: 37947202
Renal cell carcinoma (RCC), especially clear cell RCC, is generally considered an immunotherapy-responsive cancer. Recently, the prognosis for patients with locally advanced and metastatic RCC has significantly improved with the...
7.
Jones R, Fizazi K, James N, Tammela T, Matsubara N, Priou F, et al.
Prostate Cancer Prostatic Dis
. 2023 Oct;
27(4):786-789.
PMID: 37884613
Background: In patients with metastatic castration-resistant prostate cancer, darolutamide was well tolerated for 25 months, but minimal long-term safety data are available. Methods: Treatment-emergent adverse events (TEAEs) for patients receiving...
8.
Jang A, Lanka S, Jaeger E, Lieberman A, Huang M, Sartor A, et al.
JCO Precis Oncol
. 2023 Jul;
7:e2300131.
PMID: 37467457
Purpose: Circulating tumor DNA (ctDNA) detection in blood has emerged as a prognostic and predictive biomarker demonstrating improved assessment of treatment response in patients receiving immune checkpoint inhibitors (ICIs). Here,...
9.
Arenas-Gallo C, Rhodes S, Garcia J, Weinstein I, Prunty M, Lewicki P, et al.
Prostate
. 2023 Jun;
83(13):1263-1269.
PMID: 37301735
Background: Differences in DNA alterations in prostate cancer among White, Black, and Asian men have been widely described. This is the first description of the frequency of DNA alterations in...
10.
Patell K, Kurian M, Garcia J, Mendiratta P, Barata P, Jia A, et al.
Expert Rev Anticancer Ther
. 2023 May;
23(7):731-744.
PMID: 37194261
Introduction: Metastatic castrate resistant prostate cancer (mCPRC) remains an aggressive form of prostate cancer that no longer responds to traditional hormonal treatment alone. Despite the advent of novel anti-androgen medications,...